Bayer Sees Product Mix As Key To Growth In China – Emerging Market Earnings Roundup (Part 2)
This article was originally published in PharmAsia News
Executive Summary
In a recurring feature, PharmAsia News combs through quarterly earnings reports to bring you highlights on emerging markets.
You may also be interested in...
Deals of the Week: Watson/Actavis, Pfizer/Nestle, Celgene/Epizyme
With Bayer reportedly preparing to strike a multi-billion-dollar deal, investors are reacting by driving up the price of two different potential targets.
Could "Calculated Risks" In China Help Solve Global R&D Challenges? Bayer Thinks So
SHANGHAI - China could serve as the catalyst for a new model of dealmaking that emphasizes more flexible and strategic partnerships to drive R&D productivity, but only if Big Pharma is willing to take "calculated risks," according to Bayer Healthcare AG Chairman Jorg Reinhardt
With Latest Round Of Cuts, China Continues March To Narrow Gap Between Big Pharma And Local Generics
SHANGHAI - As expected, China's powerful National Development and Reform Commission announced Aug. 5 a new round of price cuts, this time targeting hormone and endocrinology drugs and central nervous system drugs, with an average cut of roughly 14%, according to analysts